Messenger RNA-based vaccines: Progress, challenges, applications

Wiley Interdisciplinary Reviews: RNA

Volumn 4, Issue 6, 2013, Pages 737-749

  Kramps, Thomas ^a,c   Probst, Jochen ^b  

^a BIONTECH AG   (Germany)

^b IDT Biologika GmbH   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOPLASMIC RECEPTOR; DNA DIRECTED RNA POLYMERASE; MESSENGER RNA; PATTERN RECOGNITION RECEPTOR; PROTEIN KINASE R; RETINOIC ACID INDUCIBLE PROTEIN I; RNA POLYMERASE; RNA VACCINE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DNA TEMPLATE; DRUG DELIVERY SYSTEM; GENETIC VARIABILITY; HETEROLOGOUS EXPRESSION; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INNATE IMMUNITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN PROCESSING; PROTEIN SYNTHESIS; RNA VECTOR; VACCINATION; VACCINE PRODUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; INFLUENZA, HUMAN; MICE; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES;

EID: 84885730496     PISSN: 17577004     EISSN: 17577012     Source Type: Journal    
DOI: 10.1002/wrna.1189     Document Type: Article

References (97)

1. Martinon F, Krishnan S, Lenzen G, Magné R, Gomard E, Guillet JG, Lévy JP, Meulien P. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 1993, 23:1719-1722.
2. Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 2011, 23:399-406.
3. Weiss R, Scheiblhofer S, Roesler E, Weinberger E, Thalhamer J. mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev Vaccines 2012, 11:55-67.
4. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen K-J, Stitz L, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012, 30:1210-1216.
5. Karikó K, Weissman D. Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel 2007, 10:523-532.
6. Der Velden AW V, Voorma HO, Thomas AA. Vector design for optimal protein expression. BioTechniques 2001, 31 572, 574, 576-580, passim.
7. Dever TE, Green R. The elongation, termination, and recycling phases of translation in eukaryotes. Cold Spring Harb Perspect Biol 2012, 4:a013706.
8. Hinnebusch AG, Lorsch JR. The mechanism of eukaryotic translation initiation: new insights and challenges. Cold Spring Harb Perspect Biol 2012, 4:a011544.
9. Plotkin JB, Kudla G. Synonymous but not the same: the causes and consequences of codon bias. Nat Rev Genet 2011, 12:32-42.
10. Fath S, Bauer AP, Liss M, Spriestersbach A, Maertens B, Hahn P, Ludwig C, Schäfer F, Graf M, Wagner R. Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One 2011, 6:e17596.
11. Ternette N, Stefanou D, Kuate S, Uberla K, Grunwald T. Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps. Virol J 2007, 4:51.
12. Starck SR, Shastri N. Non-conventional sources of peptides presented by MHC class I. Cell Mol Life Sci 2011, 68:1471-1479.
13. Angov E. Codon usage: nature's roadmap to expression and folding of proteins. Biotechnol J 2011, 6:650-659.
14. Schoenberg DR, Maquat LE. Regulation of cytoplasmic mRNA decay. Nat Rev Genet 2012, 13:246-259.
15. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Tureci O, Sahin U. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010, 70:9031-9040.
16. Eckmann CR, Rammelt C, Wahle E. Control of poly(A) tail length. WIREs: RNA 2011, 2:348-361.
17. Wilusz JE, Spector DL. An unexpected ending: noncanonical 3' end processing mechanisms. RNA 2010, 16:259-266.
18. Wilusz JE, JnBaptiste CK, Lu LY, Kuhn C-D, Joshua-Tor L, Sharp PA. A triple helix stabilizes the 3' ends of long noncoding RNAs that lack poly(A) tails. Genes Dev 2012, 26:2392-2407.
19. Fourmy D, Yoshizawa S. Protein-RNA footprinting: an evolving tool. WIREs: RNA 2012, 3:557-566.
20. Goodarzi H, Najafabadi HS, Oikonomou P, Greco TM, Fish L, Salavati R, Cristea IM, Tavazoie S. Systematic discovery of structural elements governing stability of mammalian messenger RNAs. Nature 2012, 485:264-268.
21. Fritz DT, Ford LP, Wilusz J. An in vitro assay to study regulated mRNA stability. Sci STKE 2000, 2000:pl1.
22. Grudzien-Nogalska E, Kowalska J, Su W, Kuhn AN, Slepenkov SV, Darzynkiewicz E, Sahin U, Jemielity J, Rhoads RE. Synthetic mRNAs with superior translation and stability properties. Methods Mol Biol (Clifton NJ) 2013, 969:55-72.
23. Rabinovich PM, Weissman SM. Cell engineering with synthetic messenger RNA. Methods Mol Biol (Clifton NJ) 2013, 969:3-28.
24. Kuhn AN, Diken M, Kreiter S, Vallazza B, Türeci Ö, Sahin U. Determinants of intracellular RNA pharmacokinetics: implications for RNA-based immunotherapeutics. RNA Biol 2011, 8:35-43.
25. Probst J, Fotin-Mleczek M, Schlake T, Thess A, Kramps T, Kallen K-J. Messenger RNA vaccines. In: Thalhamer J, Weiss R, Scheiblhofer S, eds. Gene Vaccines. Vienna: Springer; 2012, 223-245.
26. Rabinovich PM. Synthetic Messenger RNA and Cell Metabolism Modulation: Methods and Protocols. 2013th ed. New York: Humana Press; 2013.
27. Schlake T, Thess A, Fotin-Mleczek M, Kallen K-J. Developing mRNA-vaccine technologies. RNA Biol 2012, 9:1319-1330.
28. Moon SL, Wilusz J. In vitro transcription of modified RNAs. Methods Mol Biol (Clifton NJ) 2012, 941:171-180.
29. Karikó K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 2011, 39:e142.
30. Jones KL, Drane D, Gowans EJ. Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques 2007, 43:675-681.
31. Padilla R, Sousa R. A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non-canonical NTPs. Nucleic Acids Res 2002, 30:e138.
32. Paul S, Stang A, Lennartz K, Tenbusch M, Überla K. Selection of a T7 promoter mutant with enhanced in vitro activity by a novel multi-copy bead display approach for in vitro evolution. Nucleic Acids Res 2013, 41:e29.
33. Kiyama R, Oishi M. In vitro transcription of a poly(dA) x poly(dT)-containing sequence is inhibited by interaction between the template and its transcripts. Nucleic Acids Res 1996, 24:4577-4583.
34. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011, 12:509-517.
35. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity 2010, 33:451-463.
36. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012, 12:479-491.
37. Marino M, Scuderi F, Provenzano C, Bartoccioni E. Skeletal muscle cells: from local inflammatory response to active immunity. Gene Ther 2011, 18:109-116.
38. Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol 2009, 9:679-691.
39. McCluskie MJ, Brazolot Millan CL, Gramzinski RA, Robinson HL, Santoro JC, Fuller JT, Widera G, Haynes JR, Purcell RH, Davis HL. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med Camb Mass 1999, 5:287-300.
40. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 2005, 54:3-20.
41. Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Türeci Ö, Sahin U. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 2011, 18:702-708.
42. Lorenz C, Fotin-Mleczek M, Roth G, Becker C, Dam TC, Verdurmen WPR, Brock R, Probst J, Schlake T. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol 2011, 8:627-636.
43. Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee H-G, Pascolo S. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther 2007, 14:1175-1180.
44. DeWitte-Orr SJ, Collins SE, Bauer CMT, Bowdish DM, Mossman KL. An accessory to the "Trinity": SR-As are essential pathogen sensors of extracellular dsRNA, mediating entry and leading to subsequent type I IFN responses. PLoS Pathog 2010, 6:e1000829.
45. Scheel B, Teufel R, Probst J, Carralot J-P, Geginat J, Radsak M, Jarrossay D, Wagner H, Jung G, Rammensee H-G, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 2005, 35:1557-1566.
46. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen K-J. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011, 34:1-15.
47. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000, 30:1-7.
48. Rettig L, Haen SP, Bittermann AG, von Boehmer L, Curioni A, Krämer SD, Knuth A, Pascolo S. Particle size and activation threshold: a new dimension of danger signaling. Blood 2010, 115:4533-4541.
49. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005, 434:1035-1040.
50. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
51. Probst J, Brechtel S, Scheel B, Hoerr I, Jung G, Rammensee H-G, Pascolo S. Characterization of the ribonuclease activity on the skin surface. Genet Vaccines Ther 2006, 4:4.
52. Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee H-G, Weller M, Pascolo S. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 2006, 36:2807-2816.
53. Bianchi ME, Celona B. Ancient news: HMGBs are universal sentinels. J Mol Cell Biol 2010, 2:116-117.
54. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundbäck P, Valdes-Ferrer SI, Olofsson PS, Kalb T, Roth J, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012, 488:670-674.
55. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune system. Annu Rev Immunol 2011, 29:185-214.
56. Sander LE, Davis MJ, Boekschoten MV, Amsen D, Dascher CC, Ryffel B, Swanson JA, Müller M, Blander JM. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 2011, 474:385-389.
57. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006, 108:544-550.
58. Sarvestani ST, Williams BRG, Gantier MP. Human Toll-like receptor 8 can be cool too: implications for foreign RNA sensing. J Interf Cytokine Res 2012, 32:350-361.
59. Levy O, Suter EE, Miller RL, Wessels MR. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 2006, 108:1284-1290.
60. Karikó K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004, 279:12542-12550.
61. Sadler AJ, Williams BRG. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008, 8:559-568.
62. Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 2010, 115:1949-1957.
63. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006, 108:3253-3261.
64. Kratky W, Reis e Sousa C, Oxenius A, Spörri R. Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination. Proc Natl Acad Sci USA 2011, 108:17414-17419.
65. Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, DeFranco AL. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the anti-viral germinal center response. Immunity 2011, 34:375-384.
66. Pollard C, Rejman J, De Haes W, Verrier B, Van Gulck E, Naessens T, De Smedt S, Bogaert P, Grooten J, Vanham G, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 2013, 21:251-259.
67. Zinkernagel RM. On natural and artificial vaccinations. Annu Rev Immunol 2003, 21:515-546.
68. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996, 184:465-472.
69. Jung S, Unutmaz D, Wong P, Sano G-I, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 2002, 17:211-220.
70. Sancho D, Mourão-Sá D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, Reis e Sousa C. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 2008, 118:2098-2110.
71. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(4949 Pt 1):1465-1468.
72. Granstein RD, Ding W, Ozawa H. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 2000, 114:632-636.
73. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011, 239:62-84.
74. Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 2009, 10:1237-1244.
75. Liard C, Munier S, Joulin-Giet A, Bonduelle O, Hadam S, Duffy D, Vogt A, Verrier B, Combadière B. Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J Invest Dermatol 2012, 132(3 Pt 1):615-625.
76. Oh JZ, Kurche JS, Burchill MA, Kedl RM. TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 2011, 118:3028-3038.
77. Schulz O, Diebold SS, Chen M, Näslund TI, Nolte MA, Alexopoulou L, Azuma Y-T, Flavell RA, Liljeström P, Reis e Sousa C. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433:887-892.
78. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006, 6:231-243.
79. Petersen LR, Roehrig JT. Flavivirus DNA vaccines-good science, uncertain future. J Infect Dis 2007, 196:1721-1723.
80. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013, 31(Suppl 2):B209-B215.
81. Dörner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity 2007, 27:384-392.
82. Wong S-S, Webby RJ. An mRNA vaccine for influenza. Nat Biotechnol 2012, 30:1202-1204.
83. Cools N, Van Camp K, Van Tendeloo V, Berneman Z. mRNA electroporation as a tool for immunomonitoring. Methods Mol Biol (Clifton NJ) 2013, 969:293-303.
84. Doucet J-D, Gauchat D, Lapointe R. mRNA PCR-based epitope chase method. Methods Mol Biol Clifton Nj 2013, 969:305-320.
85. Hondowicz BD, Schwedhelm KV, Kas A, Tasch MA, Rawlings C, Ramchurren N, McIntosh M, D'Amico LA, Sanda S, Standifer NE, et al. Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries. PLoS One 2012, 7:e29949.
86. Geall AJ, Mandl CW, Ulmer JB. RNA: The new revolution in nucleic acid vaccines. Semin Immunol In press.
87. Cantara WA, Crain PF, Rozenski J, McCloskey JA, Harris KA, Zhang X, Vendeix FAP, Fabris D, Agris PF. The RNA Modification Database, RNAMDB: 2011 update. Nucleic Acids Res 2011, 39(Database issue):D195-201.
88. Friedmann T, Rossi J, Friedmann JRT. Gene Transfer: Delivery and Expression of DNA and RNA, a Laboratory Manual. 1 Lab. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2006.
89. Jacobs GH, Chen A, Stevens SG, Stockwell PA, Black MA, Tate WP, Brown CM. Transterm: a database to aid the analysis of regulatory sequences in mRNAs. Nucleic Acids Res 2009, 37(Database issue):D72-76.
90. Pisano GP. Development Factory: Unlocking the Potential of Process Innovation. Cambridge: Harvard Business Review Press; 1996. Pisano analyzes how industrial process optimization impacts value creation.
91. Jordan Report: Accelerated Development of Vaccines 2012. Available at: http://www.niaid.nih.gov/topics/vaccines/Pages/Jordan2012.aspx. Accessed May 10 2013.
92. Nakaya HI, Li S, Pulendran B. Systems vaccinology: learning to compute the behavior of vaccine induced immunity. WIREs: Syst Biol Med 2012, 4:193-205.
93. Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th revised ed. Expert Consult. Philadelphia: Saunders; 2012.
94. Rush CM, Mitchell TJ, Garside P. A detailed characterisation of the distribution and presentation of DNA vaccine encoded antigen. Vaccine 2010, 28:1620-1634.
95. The Compelling Need for Game-Changing Influenza Vaccines: An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future. Available at: http://www.cidrap.umn.edu/cidrap/files/80/ccivi%20report.pdf. Accessed May 17 2013.
96. Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine 2012, 30:4414-4418.
97. Vandenbon A, Teraguchi S, Akira S, Takeda K, Standley DM. Systems biology approaches to toll-like receptor signaling. WIREs: Syst Biol Med 2012, 4:497-507.